Research Topic

Immune-Related Adverse Events for Patients with Lung Cancer

About this Research Topic

Immunotherapy is now an effective treatment for lung cancer, supported by overall improvement of clinical outcomes and better tolerance. Common targets of immunotherapy agents include the programmed cell death protein 1 (PD-1) pathway and the cytotoxic T-lymphocyte associated protein-4 pathways (CTLA-4). However, a reinvigorated immune system may lead to disturbances in normal immune self-tolerance and, as a result, may induce off-target immune-related adverse events (irAEs). IrAEs can happen to any organ, such as lung, liver, skin, kidney, etc. For patients with lung cancer, immune-mediated lung injury occurs in about 3% to 5% of patients receiving immunotherapy, and the real-world incidence of this entity may be higher, especially now that immunotherapy is more commonly used.

The most common management strategy for irAEs is early prevention, early detection and early treatment. Most of irAEs are mild and can be managed through transient immunosuppression with corticosteroids, but high-grade events often require hospitalization and specialized treatment. Sometimes, discontinuing current therapy is necessary.

This Research Topic aims at providing a forum to update and discuss new discoveries in the field of pathogenesis and management of irAEs for patients with lung cancer, and learn their recent incidence. IrAEs discussed here refer to those caused by all types of immunotherapy methods, including mono and combination immunotherapy.

We welcome Original Research papers, Reviews, and Systematic Reviews on major trends and challenges in this field, including but not limited to:
- Recent incidence of irAEs of immunotherapy for lung cancer
- Pathogenesis of irAEs of immunotherapy for lung cancer
- Management of irAEs of immunotherapy for lung cancer


Keywords: Immune-related Adverse Events (irAE), Lung Cancer, Immunotherapy, Incidence, Management, Pathogenesis


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Immunotherapy is now an effective treatment for lung cancer, supported by overall improvement of clinical outcomes and better tolerance. Common targets of immunotherapy agents include the programmed cell death protein 1 (PD-1) pathway and the cytotoxic T-lymphocyte associated protein-4 pathways (CTLA-4). However, a reinvigorated immune system may lead to disturbances in normal immune self-tolerance and, as a result, may induce off-target immune-related adverse events (irAEs). IrAEs can happen to any organ, such as lung, liver, skin, kidney, etc. For patients with lung cancer, immune-mediated lung injury occurs in about 3% to 5% of patients receiving immunotherapy, and the real-world incidence of this entity may be higher, especially now that immunotherapy is more commonly used.

The most common management strategy for irAEs is early prevention, early detection and early treatment. Most of irAEs are mild and can be managed through transient immunosuppression with corticosteroids, but high-grade events often require hospitalization and specialized treatment. Sometimes, discontinuing current therapy is necessary.

This Research Topic aims at providing a forum to update and discuss new discoveries in the field of pathogenesis and management of irAEs for patients with lung cancer, and learn their recent incidence. IrAEs discussed here refer to those caused by all types of immunotherapy methods, including mono and combination immunotherapy.

We welcome Original Research papers, Reviews, and Systematic Reviews on major trends and challenges in this field, including but not limited to:
- Recent incidence of irAEs of immunotherapy for lung cancer
- Pathogenesis of irAEs of immunotherapy for lung cancer
- Management of irAEs of immunotherapy for lung cancer


Keywords: Immune-related Adverse Events (irAE), Lung Cancer, Immunotherapy, Incidence, Management, Pathogenesis


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

12 July 2020 Abstract
09 November 2020 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..

Topic Editors

Loading..

Submission Deadlines

12 July 2020 Abstract
09 November 2020 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..